SELLAS Life Sciences Gr Stock (NASDAQ: SLS)

SELLAS Life Sciences Gr

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

movers

News

Intraday Update

Markets

Movers

Trading Ideas

AGRI

ALLG

AMCX

ATRA

AVTE

BIMI

BJDX

BMEA

BTDR

CETX

CNSP

EVTV

FCEL

FLFV

KAVL

LRHC

LXRX

MBIO

MEDS

MIRM

MYTE

NDRA

OUST

OVID

PRMW

SCNI

SCPX

SPCE

SYNX

TRNR

VERO

WKHS

XPOF

XTLB

XXII

Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Biotech

Earnings

Penny Stocks

Upgrades

Analyst Ratings

General

Investors might want to bet on Galena Biopharma, Inc. (NASDAQ: SLS), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.

Galena Biopharma Upgraded to Buy: Here&#39;s What You Should Know

Eurozone

Commodities

Small Cap

Global

ADBE

CDLX

CISS

IMRX

VERB

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling over 200 points on Friday.

The Dow traded down 0.55% to 38,692.43 while the NASDAQ fell 0.90% to 15,982.65. The S&amp;P 500 also fell, dropping, 0.64% to 5,117.35.

Dow Falls Over 200 Points; Adobe Shares Plunge

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Group Inc

Solasto Corp

SELECT SANDS CORP ORD by Select Sands Corp.

Select Sands Corp

Solesence Inc

Solaris Resources Inc

Solaris Resources Inc Ordinary Shares

Press Releases

SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET

SELLAS Announces Key Business Objectives for 2025

Health Care

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

Opinion

Oncology Breakthroughs: How Cancer Research Is Advancing in 2025

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

AMGN

CELC

GNTA

ONCY

TSX:ONC

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

Cellectis S.A. - American Depositary Shares

Cellectis

Cardiff Oncology

Fate Therapeutics

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

TuHURA Biosciences

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

Inhibrx Biosciences

INmune Bio

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Inventiva S.A. - American Depository Shares

Inventiva

Korro Bio

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Lexeo Therapeutics

Molecular Partners AG - American Depositary Shares

Molecular Partners

Nanobiotix

Nkarta

Puma Biotechnology

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

Tango Therapeutics

Vigil Neuroscience

Cantor Fitzgerald

Alliance Global Partners

SELLAS Life Sciences

Comments

SELLAS Life Sciences Gr

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell